B. Massutí

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).

Josep Tabernero, Enrique Aranda, Alba Liliana Gil Gómez et al. · Journal of Clinical Oncology · 2010 · 39 citations

Medicine, Oncology, Pharmacology +8

Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.

Eric Van Cutsem, C. Boni, Josep Tabernero et al. · Journal of Clinical Oncology · 2011 · 23 citations

Medicine, Oncology, Pharmacology +14

Treatment of Advanced Colorectal Cancer with Recombinant Interferon Alpha and Fluorouracil: Activity in Liver Metastasis

José Jimeno, Carlos Camps, Enrique Aranda et al. · Cancer Investigation · 1992 · 22 citations

Medicine, Oncology, Pharmacology +17

A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial

Enriqueta Felip, Sanjay Popat, Urania Dafni et al. · Annals of Oncology · 2025 · 22 citations · Full text

Medicine, Oncology, Pharmacology +13

Preliminary results of a randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC)

Javier Sastre, B. Massutí, Josep Tabernero et al. · Journal of Clinical Oncology · 2005 · 19 citations

Medicine, Oncology, Pharmacology +16